Top

Digestive Diseases and Sciences

Published in:

01-01-2022 | Hepatocellular Carcinoma | Original Article

Hydroxysteroid 17-Beta Dehydrogenase 6 Is a Prognostic Biomarker and Correlates with Immune Infiltrates in Hepatocellular Carcinoma

Authors: Min Wu, Li Jiang

Published in: Digestive Diseases and Sciences | Issue 1/2022

Abstract

Background

Hepatocellular carcinoma (HCC) is a common malignancy worldwide with poor outcomes. Therefore, it is important to identify a valuable prognostic biomarker for HCC. The present study aimed to identify novel prognostic biomarkers for HCC and evaluate the potential role of hub genes in HCC.

Methods

Weighted gene co-expression network analysis and protein–protein interaction analysis were performed to identify important potential prognostic genes. The expression of hub genes was confirmed by the GEPIA, Oncomine, UALCAN, and HPA database. Furthermore, survival analysis of hub genes was performed using the Kaplan–Meier plotter database. Finally, we investigated the association between hub genes and immune factors in HCC through GSEA, the TIMER, and TISIDB database.

Results

HSD17B6 expression was significantly lower in HCC than in normal tissues. Low HSD17B6 expression is associated with poorer overall survival and progression-free survival in HCC patients, particularly at medium disease stages (stage II and III or grade III). HSD17B6 showed a strong correlation with tumor-infiltrating B cells, CD4 + and CD8 + T cells, macrophages, neutrophils, and dendritic cells. Somatic copy number alteration might be the main cause of the negative correlation between HSD17B6 expression and immune infiltration. HSD17B6 expression in HCC negatively correlated with the expression of several immune cell markers, including exhausted T cell markers, PD-1 and CTLA-4, suggesting its role in regulating tumor immunity.

Conclusions

HSD17B6 is a potential prognostic biomarker that determines cancer progression and is correlated with tumor immune cells infiltration in HCC.

Available only for authorised users

Lurje I, Czigany Z, Bednarsch J, et al. Treatment strategies for hepatocellular carcinoma (-) a multidisciplinary approach. Int J Mol Sci. 2019. https://doi.org/10.3390/ijms20061465.CrossRefPubMedPubMedCentral

Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology. 2016;150:835–853. https://doi.org/10.1053/j.gastro.2015.12.041.CrossRefPubMed

Llovet JM, Montal R, Villanueva A. Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival. J Hepatol. 2019;70:1262–1277. https://doi.org/10.1016/j.jhep.2019.01.028.CrossRefPubMed

Grandhi MS, Kim AK, Ronnekleiv-Kelly SM, Kamel IR, Ghasebeh MA, Pawlik TM. Hepatocellular carcinoma: From diagnosis to treatment. Surg Oncol. 2016;25:74–85. https://doi.org/10.1016/j.suronc.2016.03.002.CrossRefPubMed

Lu C, Rong D, Zhang B, et al. Current perspectives on the immunosuppressive tumor microenvironment in hepatocellular carcinoma: Challenges and opportunities. Mol Cancer. 2019;18:130. https://doi.org/10.1186/s12943-019-1047-6.CrossRefPubMedPubMedCentral

Cariani E, Missale G. Immune landscape of hepatocellular carcinoma microenvironment: Implications for prognosis and therapeutic applications. Liver Int Off J Int Assoc Study Liver. 2019;39:1608–1621. https://doi.org/10.1111/liv.14192.CrossRef

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–674. https://doi.org/10.1016/j.cell.2011.02.013.CrossRef

Sasada T, Suekane S. Variation of tumor-infiltrating lymphocytes in human cancers: Controversy on clinical significance. Immunotherapy. 2011;3:1235–1251. https://doi.org/10.2217/imt.11.106.CrossRefPubMed

Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer. 2009;9:239–252. https://doi.org/10.1038/nrc2618.CrossRefPubMed

10.

Prieto J, Melero I, Sangro B. Immunological landscape and immunotherapy of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2015;12:681–700. https://doi.org/10.1038/nrgastro.2015.173.CrossRefPubMed

11.

Liu X, Qin S. Immune checkpoint inhibitors in hepatocellular carcinoma: Opportunities and challenges. Oncologist. 2019;24:S3–S10. https://doi.org/10.1634/theoncologist.2019-io-s1-s01.CrossRefPubMedPubMedCentral

12.

Tovoli F, Casadei-Gardini A, Benevento F, Piscaglia F. Immunotherapy for hepatocellular carcinoma: A review of potential new drugs based on ongoing clinical studies as of 2019. Digest Liver Dis Off J Italian Soc Gastroenterol Italian Assoc Study Liver. 2019;51:1067–1073. https://doi.org/10.1016/j.dld.2019.05.006.CrossRef

13.

Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016;16:275–287. https://doi.org/10.1038/nrc.2016.36.CrossRefPubMedPubMedCentral

14.

Kudo M. Immune checkpoint inhibition in hepatocellular carcinoma: Basics and ongoing clinical trials. Oncology. 2017;92:50–62. https://doi.org/10.1159/000451016.CrossRefPubMed

15.

Lu LC, Hsu C, Shao YY, et al. Differential organ-specific tumor response to immune checkpoint inhibitors in hepatocellular carcinoma. Liver Cancer. 2019;8:480–490. https://doi.org/10.1159/000501275.CrossRefPubMedPubMedCentral

16.

Zhou Z, Cheng Y, Jiang Y, et al. Ten hub genes associated with progression and prognosis of pancreatic carcinoma identified by co-expression analysis. Int J Biol Sci. 2018;14:124–136. https://doi.org/10.7150/ijbs.22619.CrossRefPubMedPubMedCentral

17.

Qi YF, Sun JN, Ren LF, et al. Intestinal microbiota is altered in patients with gastric cancer from Shanxi Province, China. Dig Dis Sci. 2019;64:1193–1203. https://doi.org/10.1007/s10620-018-5411-y.CrossRefPubMed

18.

Jones MR, Italiano L, Wilson SG, et al. Polymorphism in HSD17B6 is associated with key features of polycystic ovary syndrome. Fertil Steril. 2006;86:1438–1446. https://doi.org/10.1016/j.fertnstert.2006.04.027.CrossRefPubMed

19.

Zhang A, Zhang J, Plymate S, Mostaghel EA. Classical and non-classical roles for pre-receptor control of DHT metabolism in prostate cancer progression. Hormones Cancer. 2016;7:104–113. https://doi.org/10.1007/s12672-016-0250-9.CrossRefPubMedPubMedCentral

20.

Jernberg E, Thysell E, Bovinder Ylitalo E, et al. Characterization of prostate cancer bone metastases according to expression levels of steroidogenic enzymes and androgen receptor splice variants. PLoS ONE. 2013;8:e77407. https://doi.org/10.1371/journal.pone.0077407.CrossRefPubMedPubMedCentral

21.

Ma Q, Xu Y, Liao H, et al. Identification and validation of key genes associated with non-small-cell lung cancer. J Cell Physiol. 2019;234:22742–22752. https://doi.org/10.1002/jcp.28839.CrossRefPubMed

22.

White DL, Liu Y, Garcia J, et al. Sex hormone pathway gene polymorphisms are associated with risk of advanced hepatitis C-related liver disease in males. Int J Mol Epidemiol Genet. 2014;5:164–176.PubMedPubMedCentral

23.

Yang JD, Seol SY, Leem SH, et al. Genes associated with recurrence of hepatocellular carcinoma: integrated analysis by gene expression and methylation profiling. J Korean Med Sci. 2011;26:1428–1438. https://doi.org/10.3346/jkms.2011.26.11.1428.CrossRefPubMedPubMedCentral

24.

Han JM, Kang JA, Han MH, et al. Peroxisome-localized hepatitis Bx protein increases the invasion property of hepatocellular carcinoma cells. Adv Virol. 2014;159:2549–2557. https://doi.org/10.1007/s00705-014-2105-4.CrossRef

25.

Cai M, Sun X, Wang W, et al. Disruption of peroxisome function leads to metabolic stress, mTOR inhibition, and lethality in liver cancer cells. Cancer Lett. 2018;421:82–93. https://doi.org/10.1016/j.canlet.2018.02.021.CrossRefPubMed

26.

Di Cara F, Andreoletti P, Trompier D, et al. Peroxisomes in immune response and inflammation. Int J Mol Sci. 2019;20:3877. https://doi.org/10.3390/ijms20163877.CrossRefPubMedCentral

27.

Jeng KS, Chang CF, Jeng WJ, Sheen IS, Jeng CJ. Heterogeneity of hepatocellular carcinoma contributes to cancer progression. Crit Rev Oncol Hematol. 2015;94:337–347. https://doi.org/10.1016/j.critrevonc.2015.01.009.CrossRefPubMed

28.

Fu Y, Liu S, Zeng S, Shen H. From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma. J Exp Clin Cancer Res. 2019;38:396. https://doi.org/10.1186/s13046-019-1396-4.CrossRefPubMedPubMedCentral

29.

Sachdeva M, Chawla YK, Arora SK. Immunology of hepatocellular carcinoma. World J Hepatol. 2015;7:2080–2090. https://doi.org/10.4254/wjh.v7.i17.2080.CrossRefPubMedPubMedCentral

30.

Zhang S-C, Hu Z-Q, Long J-H, et al. Clinical implications of tumor-infiltrating immune cells in breast cancer. J Cancer.. 2019;10:6175–6184. https://doi.org/10.7150/jca.35901.CrossRefPubMedPubMedCentral

31.

Ye L, Zhang T, Kang Z, et al. Tumor-infiltrating immune cells act as a marker for prognosis in colorectal cancer. Front Immunol. 2019. https://doi.org/10.3389/fimmu.2019.02368.CrossRefPubMedPubMedCentral

32.

Pagès F, Galon J, Dieu-Nosjean MC, Tartour E, Sautès-Fridman C, Fridman WH. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene. 2010;29:1093–1102. https://doi.org/10.1038/onc.2009.416.CrossRefPubMed

33.

Guo F, Dong Y, Tan Q, Kong J, Yu B. Tissue infiltrating immune cells as prognostic biomarkers in endometrial cancer: A meta-analysis. Dis Mark. 2020;2020:1805764. https://doi.org/10.1155/2020/1805764.CrossRef

34.

Li T, Fu J, Zeng Z, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucl Acids Res. 2020;48:W509–W514. https://doi.org/10.1093/nar/gkaa407.CrossRefPubMedPubMedCentral

35.

Aran D, Hu Z, Butte AJ. xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 2017;18:220. https://doi.org/10.1186/s13059-017-1349-1.CrossRefPubMedPubMedCentral

36.

Newman AM, Liu CL, Green MR, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12:453–457. https://doi.org/10.1038/nmeth.3337.CrossRefPubMedPubMedCentral

37.

Becht E, Giraldo NA, Lacroix L, et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 2016;17:218. https://doi.org/10.1186/s13059-016-1070-5.CrossRefPubMedPubMedCentral

38.

Racle J, de Jonge K, Baumgaertner P, Speiser DE, Gfeller D. Simultaneous enumeration of cancer and immune cell types from bulk tumor gene expression data. eLife. 2017;6:e26476. https://doi.org/10.7554/elife.26476.CrossRefPubMedPubMedCentral

39.

Finotello F, Mayer C, Plattner C, et al. Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data. Genome Med. 2019;11:34. https://doi.org/10.1186/s13073-019-0638-6.CrossRefPubMedPubMedCentral

40.

Urrutia E, Chen H, Zhou Z, Zhang NR, Jiang Y. Integrative pipeline for profiling DNA copy number and inferring tumor phylogeny. Bioinformatics. 2018;34:2126–2128. https://doi.org/10.1093/bioinformatics/bty057.CrossRefPubMedPubMedCentral

41.

Balkwill F. Cancer and the chemokine network. Nat Rev Cancer. 2004;4:540–550. https://doi.org/10.1038/nrc1388.CrossRefPubMed

42.

Granier C, De Guillebon E, Blanc C, et al. Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer. ESMO Open. 2017;2:e000213. https://doi.org/10.1136/esmoopen-2017-000213.CrossRefPubMedPubMedCentral

43.

Philips GK, Atkins M. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies. Int Immunol. 2015;27:39–46. https://doi.org/10.1093/intimm/dxu095.CrossRefPubMed

44.

Vongsa RA, Zimmerman NP, Dwinell MB. CCR6 regulation of the actin cytoskeleton orchestrates human beta defensin-2- and CCL20-mediated restitution of colonic epithelial cells. J Biol Chem. 2009;284:10034–10045. https://doi.org/10.1074/jbc.m805289200.CrossRefPubMedPubMedCentral

45.

Al-Alem L, Puttabyatappa M, Rosewell K, et al. Chemokine ligand 20: A signal for leukocyte recruitment during human ovulation? Endocrinology. 2015;156:3358–3369. https://doi.org/10.1210/en.2014-1874.CrossRefPubMedPubMedCentral

46.

Rodríguez-Perea AL, Rojas M, Velilla-Hernández PA. High concentrations of atorvastatin reduce in vitro function of conventional T and regulatory T cells. Clin Exp Immunol. 2019;196:237–248. https://doi.org/10.1111/cei.13260.CrossRefPubMedPubMedCentral

47.

Shigeta K, Datta M, Hato T, et al. Dual programmed death Receptor-1 and vascular endothelial growth factor Receptor-2 blockade promotes vascular normalization and enhances antitumor immune responses in hepatocellular carcinoma. Hepatology (Baltimore, MD). 2020;71:1247–1261. https://doi.org/10.1002/hep.30889.CrossRef

Title: Hydroxysteroid 17-Beta Dehydrogenase 6 Is a Prognostic Biomarker and Correlates with Immune Infiltrates in Hepatocellular Carcinoma
Authors: Min Wu
Li Jiang
Publication date: 01-01-2022
Publisher: Springer US
Keywords: Hepatocellular Carcinoma
Hepatocellular Carcinoma
Biomarkers
Published in: Digestive Diseases and Sciences / Issue 1/2022
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-021-06832-7

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2022

Severe Upper Gastrointestinal Hemorrhage Caused by Reflux Esophagitis

No Evidence Indicates Famotidine Reduces the Risk of Serious Disease in COVID-19 Patients After Propensity Score Matching: Meta-Analysis and Systematic Reviews

Disparities in Telehealth for Liver Disease: Revealing What Was Hidden in Plain Sight

Acceptability and Adequacy of a Non-endoscopic Cell Collection Device for Diagnosis of Barrett’s Esophagus: Lessons Learned

Nonalcoholic Fatty Pancreas Disease: Role in Metabolic Syndrome, “Prediabetes,” Diabetes and Atherosclerosis

Letter to the Editor on “Treatment Adherence and Clinical Outcomes of Patients with Inflammatory Bowel Disease Patients During the SARS-CoV-2 Pandemic”

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage